CVS Health is one of the biggest pharmacy chains in America, with about 9,000 stores, a massive pharmacy benefits manager (Caremark), a health insurance business (Aetna), and revenue north of 370 billion dollars a year. It is also one of the single hardest BRI calls for any fund manager who takes the abortion screen seriously.

Let me explain why, and how different BRI funds have landed on the question.

What CVS dispenses

Since the Dobbs decision in 2022, the landscape for abortion drugs in the US has shifted. Mifepristone (sold as Mifeprex and generic versions) is the drug used in most medication abortions. The FDA first approved it in 2000 but restricted distribution through REMS (Risk Evaluation and Mitigation Strategies) rules that limited which pharmacies could dispense it.

In January 2023, the FDA updated those rules to allow retail pharmacies to dispense mifepristone with a prescription, provided the pharmacy completed a certification process. Walgreens initially said they would not dispense it in states where attorneys general threatened legal action. CVS took a similar approach at first, then shifted to a more state-by-state position.

As of early 2026, CVS dispenses mifepristone in states where it is legal to do so. CVS also sells Plan B and Ella (emergency contraception) over the counter in every state, as they have for years.

For BRI funds with an abortion screen, both of these matter.

The Plan B question is its own debate

Here is where Christians actually disagree among themselves. Plan B (levonorgestrel) works primarily by delaying ovulation, and the evidence suggests its main mechanism is preventing fertilization rather than preventing implantation. Some Christian bioethicists argue Plan B is not abortifacient in practice. Others argue that even a small possibility of preventing implantation after fertilization counts, because conception has occurred.

Catholic teaching treats Plan B as impermissible in most cases. Protestant BRI funds are split. Some screen CVS specifically because of Plan B. Others take the view that Plan B is contraception rather than abortion and do not weight it heavily.

Mifepristone is the clearer case. It is unambiguously an abortion drug. A medication abortion using mifepristone and misoprostol ends an existing pregnancy. Every BRI fund that has a real abortion screen treats mifepristone as a defining issue.

How the major BRI funds handle CVS

Timothy Plan excludes CVS. They have been strict on this for years and the post-Dobbs pharmacy decisions made their exclusion more obvious.

Inspire's BIBL excludes CVS. The Inspire Impact Score for CVS is negative, driven primarily by the mifepristone dispensing decision plus corporate giving to organizations Inspire flags.

Eventide does not own CVS in its flagship funds, though the reasoning is not exclusively the mifepristone issue. Eventide also flags concerns about pharmacy benefits manager practices and how CVS's Caremark unit handles pricing for customers.

GuideStone has a more moderate screen and has owned CVS at various times. Their current position as of early 2026 is that CVS is not in the Equity Income fund but has appeared in some sector-specific allocations depending on the methodology.

Praxis does not own CVS.

So CVS is mostly excluded from BRI portfolios, but the reasoning is layered. It is not just "CVS dispenses an abortion drug." It is "CVS dispenses an abortion drug, sells emergency contraception, donates to some advocacy groups, and has business practices at Caremark that raise separate stewardship questions."

The biblical framework

Psalm 139:13-16 is the central text. "For you formed my inward parts; you knitted me together in my mother's womb." Jeremiah 1:5, "Before I formed you in the womb I knew you." Exodus 21:22-25 addresses injury to an unborn child in a way that has been interpreted by most conservative Christian traditions as recognizing the unborn as fully persons.

The BRI position on abortion is not that everyone who takes mifepristone is evil. It is that ending a pregnancy is ending a human life, and facilitating that ending, including as a pharmacy that dispenses the drug that does it, implicates the pharmacy company in the outcome.

This is a harder argument to make than the alcohol argument because pharmacies dispense a thousand other drugs that are unambiguously good. CVS fills prescriptions for insulin, antibiotics, cancer medications. The moral case against the company has to be specific to the abortion drug dispensing, not a blanket judgment on pharmacies.

The counterargument some Christians make

A reasonable pushback goes like this. Pharmacies are regulated businesses. They dispense what the FDA has approved. A pharmacist following the law is not the moral agent of each individual patient's choice. If you exclude CVS for mifepristone, you should exclude every hospital system, every insurance company, every supply chain partner involved in any way with abortion. And if you go that far, you will find that it is almost impossible to own a healthcare portfolio at all.

This is not a crazy argument. It has some weight. The BRI response is usually that there is a difference between a hospital where individual doctors make individual patient decisions versus a corporation that has publicly committed to distributing a specific abortion drug as part of its business model. CVS made the choice to dispense mifepristone. They did not have to. Some independent pharmacies refused. The corporate decision is what BRI funds hold against the stock.

The Walgreens comparison

Walgreens Boots Alliance (WBA) is in the same industry and faces the same question. Walgreens was more publicly hesitant about dispensing mifepristone initially, which caused its own backlash from progressive advocacy groups. By 2024, Walgreens had also committed to dispensing mifepristone in legal states.

BRI funds treat WBA similarly to CVS. Both are excluded by the strict funds. WBA has had an even worse financial performance than CVS, trading in the low single digits at various points in 2024 after the company's long struggle to compete with Amazon and mail order pharmacy disruption. For BRI investors, avoiding WBA was also a financial blessing.

What about Walmart pharmacy

Walmart (WMT) also dispenses mifepristone through its pharmacy counters in states where it is legal. Walmart is a harder screen because the pharmacy is a small fraction of Walmart's overall business. This is where the revenue threshold test matters. If pharmacy mifepristone is less than 1 percent of Walmart's revenue, some BRI funds will not exclude the whole company on that basis alone.

The result is that Walmart sits in a gray zone. Inspire excludes WMT. Eventide and GuideStone have at times owned WMT because the direct abortion drug exposure is small relative to the business. This is the kind of judgment call where BRI funds diverge, and reasonable Christians can disagree.

The Christian pharmacy alternative

There are actually Christian pharmacy networks that refuse to dispense abortion drugs and Plan B. The Catholic Pharmacists Association has been pushing this model for years. Some independent pharmacies in smaller towns operate on explicitly Christian principles and will not fill certain prescriptions. For consumers who want to avoid CVS or Walgreens, these alternatives exist, though they are not always convenient.

From an investing perspective, none of these networks are publicly traded. You can support them as a customer but not as a shareholder.

What you can do as an investor

If you want to exclude CVS from your portfolio, you have a few options. Buy a BRI fund that already excludes it. Use direct indexing to exclude specific pharmacy names. Or if you own broad market funds and are not willing to give that up, you can at least direct new contributions toward BRI-aligned vehicles rather than increasing your CVS exposure.

Also consider the Aetna piece. CVS owns Aetna, one of the largest health insurers in the US. Aetna's coverage decisions affect millions of patients and include coverage for abortion services in some plans. This adds another layer to the moral evaluation that BRI funds weigh when looking at CVS as a whole.

The stock itself

CVS stock has been weak. It traded around 110 dollars in mid-2022, dropped to the 50s and 60s through 2023 and 2024 on concerns about the Caremark business and margin pressure in the Aetna segment. By early 2026, CVS is trading in the high 60s, with a dividend yield around 4.5 percent. Some investors see it as cheap. BRI funds see it as excluded for reasons that go beyond valuation.

Philippians 4:8 says, "Whatever is true, whatever is honorable, whatever is just, whatever is pure, whatever is lovely, whatever is commendable, if there is any excellence, if there is anything worthy of praise, think about these things." Paul is talking about the habits of the mind, but BRI advocates apply the principle to the habits of the portfolio too. Where you direct your capital is where you direct your attention.

For most BRI investors, CVS does not clear the bar. The pharmacy issue is real, the corporate decisions are documented, and the alternatives exist. Skip it and sleep better.

CVS Health (CVS) and the Plan B Pharmacy Issue